At the conclusion of the inspection, the USFDA issued a Form-483, with 7 observations

Consequent to the above acquisition, Yapan has ceased to be an associate company and has become a subsidiary of the Company

With the issuance of the EIR, the inspection has now been successfully closed by the USFDA

The receipt of said EIR marks successful closure of the inspection

At the conclusion of the inspection, USFDA issued a Form-483, with three observations

Consolidated total income of the company increased by 0.06% at Rs 2,797.83 crore for Q4FY26

The receipt of said EIR marks successful closure of the inspection

Piramal Critical Care B.V. has successfully completed the acquisition of ‘Kenalog’ from Bristol-Myers Squibb Company

At the conclusion of the inspection, the US FDA issued a Form-483, with 4 observations

PCC will process captured waste anaesthetic gas using BlueZone’s technology to produce Sevoflurane USP for human use in Canada

Total consolidated income of the company decreased by 1.50% at Rs 2,183.11 crore for Q3FY26

The said acquisition is expected to further leverage the company’s extensive distribution network spanning across 6,000 plus hospitals in more than 100 countries

At the conclusion of the inspection, the USFDA issued a Form-483, with four observations

This addition will increase operational efficiency, helping NewAmsterdam Pharma to deliver its investigational drug therapy, if approved, to patients in need

The consolidated total income of the company increased by 1.09% at Rs 1992.11 crore for Q1FY26

The inspection was completed successfully with Zero Form - 483 observations

The total consolidated income of the company increased by 8.43% at Rs 2,796.10 crore for Q4FY25

The company has received the EIR for its Turbhe facility

The Transaction is expected to be completed within a period of around 6 months approximately

Through this partnership, the company combines its innovative ‘High Tech + High Touch’ approach with the financial and banking expertise of ICICI Bank

This would boost the company’s capability to also tap into inhalation anesthesia opportunities in the ROW markets in addition to the USA markets

PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions

On conclusion of the inspection, a Form-483 was issued with 6 observations

With this launch, PCC continues to expand their generic injectables portfolio

Consolidated total income of the company increased by 17.46% at Rs 2302.86 crore for Q2FY25

Upon completion of the expansion in Q1 of 2027, this capacity will increase to over 240 annual batches

Piramal Pharma has committed to reduce absolute scope 1 and 2 GHG emissions 42% by FY2030 from a FY2022 base year

The launch of BOHEM aligns with the company’s long-standing desire to cater to the male grooming market

On conclusion of the inspection, a Form-483 was issued with 2 observations

On conclusion of the inspection, a Form-483 was issued with 3 observations

The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio

The inspection has now been successfully closed by the USFDA

This new expansion significantly adds primary and secondary screening capabilities of compounds prepared at the Ahmedabad site

On conclusion of the inspection, a Form-483 was issued with 2 observations

Proceeds of the issue will be utilised for payment of debt and general corporate purposes

Total consolidated income of the company decreased by 0.97% at Rs 2,188.08 crore for Q4FY23

The inspection has now been successfully closed by the USFDA

Total consolidated income of the company increased by 5.81% to Rs 1,798.51 crore for Q3FY23

At the conclusion of the inspection, the USFDA issued a Form-483, with six observations

Total consolidated income of the company increased by 10.70% to Rs 1,766.23 crore for Q2FY23